# Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)

> **NCT06568367** · PHASE3 · RECRUITING · sponsor: **Axsome Therapeutics, Inc.** · enrollment: 520 (estimated)

## Conditions studied

- Excessive Sleepiness
- Shift-work Disorder

## Interventions

- **DRUG:** Solriamfetol 150 mg
- **DRUG:** Solriamfetol 300 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06568367
- **Lead sponsor:** Axsome Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 520 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06568367

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06568367, "Studying Solriamfetol Modulation of TAAR-1, Dopamine, and Norepinephrine in Shift Work Disorder (SUSTAIN)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06568367. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*